Market Overview:
The global Tocilizumab market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of autoimmune diseases, increasing R&D investments by pharmaceutical companies, and growing demand for Tocilizumab in emerging markets. However, the high cost of treatment is expected to restrain the growth of this market during the forecast period. The global Tocilizumab market can be segmented on the basis of type, application, and region. On the basis of type, it can be divided into min purity less than 98%, min purity 98%-99%, and min purity more than 99%. On the basis of application, it can be classified into research and medical applications. Geographically, it can be segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa .
Product Definition:
Tocilizumab is a therapy used to treat moderate to severe rheumatoid arthritis in adults. It belongs to a class of medications called monoclonal antibodies. Tocilizumab blocks the action of a protein called interleukin-6 (IL-6), which is thought to play a role in the development and progression of rheumatoid arthritis.
Min Purity Less Than 98%:
Min Purity Less Than 98% is a novel monoclonal antibody drug product that is under clinical investigation. It has been reported to have superior properties in terms of efficacy and safety when compared to the existing portfolio of TOCILIZUMAB products. Min Purity Less Than 98% consists of an optimized humanized monoclonal antibody, which binds with greater affinity than any other humanized antibody currently available in the market.
Min Purity 98%-99%:
Min Purity 98%-99% is a small range of purity level which means that the final product should contain less than 0.5% impurities by weight. It is used as an excipient for the manufacturing of tocilizumab, which is used for treatment against multiple myeloma and leukemia.
Application Insights:
The research application dominated the global market with a share of over 80.0% in 2017. The high share is attributable to the rising number of clinical trials that are being conducted for various diseases, such as diabetes and rheumatoid arthritis. Tocilizumab is approved by FDA for use in treating diabetic retinopathy and diabetic macular edema, but it has not been studied extensively for other indications yet. Hence, there is an increasing demand for tocilizumab drugs from third party payers (i.e., insurers) that are conducting clinical trials on its own initiative or at the request of government authorities responsible for formulating health policies related to vision care treatment guidelines across the globe.
Medical application was valued over USD 200 million in 2017 owing to growing usage of this drug as monotherapy or combination therapy against psoriasis vulgaris and psoriatic arthritis among others in various countries including Germany, U.K.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and rising incidence of cancer are some factors responsible for its growth. In addition, increasing R&D activities and growing healthcare expenditure are expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China & India. Furthermore, an increase in government initiatives aimed at increasing awareness regarding target diseases is also likely to boost revenue generation capacity over this period.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global incidence of autoimmune diseases is increasing at a significant rate. This is expected to drive the demand for Tocilizumab in the coming years.
- Growing awareness about Tocilizumab: There is a growing awareness about the benefits of Tocilizumab among healthcare professionals and patients alike. This is likely to boost its demand in the near future.
- Rising number of clinical trials for Tocilizumab: A large number of clinical trials are being conducted for Tocilizumab across the globe, which is indicative of its potential therapeutic benefits. This is likely to fuel its market growth in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Tocilizumab Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Medical
By Companies
Bio-Rad Laboratories, Bio-Techne, BioVision, Selleck Chemicals, Biorbyt, AbMole, Biosynth Carbosynth, SimSon Pharma, BOC Sciences, Clearsynth, LifeSpan BioSciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
176
Number of Tables & Figures
124
Customization Available
Yes, the report can be customized as per your need.
Global Tocilizumab Market Report Segments:
The global Tocilizumab market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Medical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bio-Rad Laboratories
- Bio-Techne
- BioVision
- Selleck Chemicals
- Biorbyt
- AbMole
- Biosynth Carbosynth
- SimSon Pharma
- BOC Sciences
- Clearsynth
- LifeSpan BioSciences
Highlights of The Tocilizumab Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Medical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tocilizumab Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tocilizumab is a monoclonal antibody that blocks the activity of tumor necrosis factor alpha (TNF-α). Tocilizumab is used to treat rheumatoid arthritis, an autoimmune disease in which the body's immune system attacks its own tissues.
Some of the key players operating in the tocilizumab market are Bio-Rad Laboratories, Bio-Techne, BioVision, Selleck Chemicals, Biorbyt, AbMole, Biosynth Carbosynth, SimSon Pharma, BOC Sciences, Clearsynth, LifeSpan BioSciences.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tocilizumab Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tocilizumab Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tocilizumab Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tocilizumab Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tocilizumab Market Size & Forecast, 2020-2028
4.5.1 Tocilizumab Market Size and Y-o-Y Growth
4.5.2 Tocilizumab Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Medical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tocilizumab Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tocilizumab Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Medical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Medical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Medical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Medical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Medical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tocilizumab Market: Competitive Dashboard
14.2 Global Tocilizumab Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bio-Rad Laboratories
14.3.2 Bio-Techne
14.3.3 BioVision
14.3.4 Selleck Chemicals
14.3.5 Biorbyt
14.3.6 AbMole
14.3.7 Biosynth Carbosynth
14.3.8 SimSon Pharma
14.3.9 BOC Sciences
14.3.10 Clearsynth
14.3.11 LifeSpan BioSciences
